In mid-2022, 118 drugs were on the FDA’s list.
New additions and updates to the database include cisplatin, a drug used for multiple cancers; atropine sulfate injection, which blocks severe muscarinic effects; and lidocaine hydrochloride oral topical solutions, a local anesthetic.
After months of worsening shortages for cisplatin and other cancer therapies, the FDA allowed a China-based drug company to produce and import cisplatin, and the American Society of Clinical Oncology and the Society of Gynecologic Oncology recommended reserving supply for some patients.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
